Pattern of Microbial Infection in AECOPD Patients and Its Sensitivity to Antibiotics


Assiut University


Not yet enrolling


Acute Exacerbation COPD

Study type


Funder types



Bacteriology in AECOPD

Details and patient eligibility


Measurement of bacterial species causing AECOPD and their Sensitivity pattern to antibiotics.

Full description

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality worldwide. Acute exacerbation is a common problem during the natural course of COPD, which is characterized by an increase in the patient's daily symptoms of dyspnea, cough, and/or sputum beyond normal day-to-day variability and severe enough to require an additional therapy. The most common cause of acute exacerbations of COPD (AECOPD) is an infection of the tracheobronchial tree and air pollution. As many as one-third of AECOPD causes are never identified. The microbial aetiology of AECOPD includes bacteria and viruses with more than 50% of cases being caused by bacterial infection. The bacterial etiologies of AECOPD keep changing from time to time and the choice of antimicrobial depends upon on local prevalence of bacterial etiologies and their resistance pattern. Antibiotics are the main form of treatment for AECOPD which are often initiated empirically based on healthcare provider's previous experiences , which often lead to the inappropriate use of antibiotics , thereby contributing to Antimicrobial Resistance. Early diagnosis and knowledge of the predominant bacterial etiologies and antimicrobial resistance patterns will also help to correct treatment protocol for the management of AECOPD.


140 estimated patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  • Must be at least 18 years of age and less than 80 years of age for both genders
  • Confirmed diagnosis of COPD by spirometry
  • Must be an AECOPD patient (with increased grade of dyspnea, increased purulence and amount of sputum) and admitted to the chest department or ICU
  • Positive sputum culture

Exclusion criteria

  • Age less than 18 years old
  • Any associated pulmonary co-morbidity

Trial contacts and locations



Central trial contact

Mariam Nazif Abdel-Tawab, MD; Ahmed H Mohammed, Professor

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems